Clinical trials: Phase 1
Chronic Lymphocytic Leukemia
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
This research study is evaluating a new drug called IPI-145 in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR), as a possible treatment for chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02158091
- Testing
- IPI-145, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab and combination chemotherapy and to see how well it works in treating patients with newly diagnosed stage II, stage…
- Conditions
- Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Trial name
- NCT00972478
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 190 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural…
- Conditions
- Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
- Trial name
- NCT01064648
- Testing
- Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis
- Where
- 230 sites in United States
- Volunteers
- 117 people
- Sponsor
- National Cancer Institute (NCI)
Solid Neoplasms
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone…
- Trial name
- iintune-1 (NCT04420884)
- Testing
- Dazostinag, Pembrolizumab, Platinum
- Where
- 62 sites in United States, Austria and 9 more
- Volunteers
- 248 people
- Sponsor
- Takeda
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
This phase Ib/II trial studies the side effects of IRX-2, cyclophosphamide, and pembrolizumab work in treating participants with gastric or gastroesophageal junction cancer that has come back or that has spread to other places in…
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT03918499
- Testing
- Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT02993146
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
- Where
- 14 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Sars-CoV2, Acute Respiratory Distress Syndrome
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
*At this time, we are only enrolling at Houston Methodist Hospital (HMH)/Baylor College of Medicine (BCM) and are not shipping cells outside of BCM/HMH.* This is a study for patients who have respiratory infection caused by…
- Conditions
- Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
- Trial name
- NCT04345601
- Testing
- Mesenchymal Stromal Cells, Supportive Care
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
Tumors
Phase 1 Study of E7090 in Subjects With Solid Tumor
This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts: 1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects…
- Trial name
- NCT02275910
- Testing
- E7090
- Where
- 18 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Eisai Co., Ltd.
Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with…
- Trial name
- J-MIND (NCT04661007)
- Testing
- tafasitamab, lenalidomide, parsaclisib
- Where
- 23 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Incyte Biosciences Japan GK
Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I/II partially randomized trial studies the side effects and best dose of veliparib when given together with radiation therapy, carboplatin, and paclitaxel and to see how well it works in treating patients with stage…
- Conditions
- Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma
- Trial name
- NCT01386385
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis
- Where
- 232 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Primary Effusion Lymphoma, B-Cell Neoplasm
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Background: Primary effusion lymphoma (PEL) is a rare disease with no standard treatment. Researchers want to see if a drug called lenalidomide along with common chemotherapy drugs may be effective in treating PEL.
- Trial name
- NCT02911142
- Testing
- Lenalidomide, Rituximab, Prednisone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Healthy, Renal Impairment
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood.
- Trial name
- NCT06643377
- Testing
- Enlicitide
- Where
- 5 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03206047
- Testing
- Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine
- Where
- 17 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Epilepsy
Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy
This is a Phase 1/2a, open-label, single-dose, PK study of VALTOCO with open-label safety period in pediatric epilepsy subjects age 2 to 5 years.
- Trial name
- NCT05076838
- Testing
- Diazepam Nasal Spray [Valtoco]
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Neurelis, Inc.
Healthy Volunteers
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
The primary objective of this study was to assess the effect of a cytochrome P450 3A4 (CYP3A4) inhibitor (itraconazole) and CYP3A4 inducer (carbamazepine) on the single dose pharmacokinetics (PK) of DC-806 coadministered with…
- Trial name
- NCT05994807
- Testing
- DC-806, Itraconazole, Carbamazepine
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Healthy, Obesity, Metabolically
A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities.
- Trial name
- NCT05378893
- Testing
- DR10624 for injection
- Where
- New Zealand
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Healthy Participants
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
The main objective of this study is to assess the effect of DC-806 on the pharmacokinetics (PK) of cytochrome 3A4 (CYP3A4) substrate, midazolam and its active metabolite, 1-hydroxymidazolam, cytochrome 2C8 (CYP2C8) substrate…
- Trial name
- NCT06092931
- Testing
- DC-806, Midazolam, Repaglinide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Colorectal Cancer Metastatic
EO4010 in Previously Treated Metastatic Colorectal Carcinoma
Open-label multicenter study
- Trial name
- AUDREY (NCT05589597)
- Testing
- EO4010
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 25 people
- Sponsor
- Enterome
Acute Myeloid Leukemia
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
This was a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or…
- Trial name
- NCT06508489
- Testing
- SAR443579, venetoclax, azacitidine
- Where
- 7 sites in United States, Australia
- Volunteers
- 7 people
- Sponsor
- Sanofi
Medulloblastoma, Childhood, Medulloblastoma Recurrent
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
This is a multi center, Phase I, Phase II and surgical study of the CX-4945 drug (silmitasertib sodium) for patients with recurrent SHH (Sonic Hedgehog) medulloblastoma
- Conditions
- Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
- Trial name
- NCT03904862
- Testing
- CX 4945
- Where
- 12 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pediatric Brain Tumor Consortium